Patients with metastatic non-small cell lung cancer (NSCLC) who have a rearrangement in the anaplastic lymphoma kinase (ALK) gene now have a first-line option: ceritinib.
Patients with metastatic non-small cell lung cancer (NSCLC) who have a rearrangement in the anaplastic lymphoma kinase (ALK) gene, as detected by an FDA-approved test, and who are treatment naïve can now be treated with the tyrosine kinase inhibitor ceritinib (Zykadia). The approval follows a priority review received in January 2017 for first-line in patients with ALK-positive metastatic NSCLC.
Results from the randomized, open-label, multicenter ASCEND-4 trial in patients newly diagnosed with ALK-positive NSCLC were the basis of the current approval. The rearrangement was detected using the VENTANA ALK (D5F3) test.
ASCEND-4 recruited 376 patients who were randomized 1:1 to receive once-daily ceritinib till disease progression or platinum-pemetrexed doublet chemotherapy (either cisplatin or carboplatin).
Patients were evaluated based on a blinded independent review committee assessment. Ceritinib treatment improved progression-free survival (PFS) by 8.5 months: median PFS was 16.6 months in the ceritinib arm (95% CI, 12.6 to 27.2) compared with 8.1 months in the chemotherapy arm (95% CI, 5.8 to 11.1). Patients treated with ceritinib had an objective response rate of 73% (95% CI, 66% to 79%) as opposed to 27% (95% CI, 21% to 34%) in the chemotherapy arm. The median duration of response was significantly greater among patients treated with ceritinib: 23.9 months (95% CI, 16.6 to not estimable), versus 11.1 months in those receiving chemotherapy.
Ceritinib also had an overall intracranial response rate of 57% in patients with brain metastases (95% CI, 37 to 76), versus 22% in those receiving chemotherapy (95% CI, 9 to 42).
It’s still too early to estimate overall survival in the enrolled population.
The most common adverse events (AEs) in patients receiving ceritinib were diarrhea, nausea, vomiting, fatigue, abdominal pain, decreased appetite, and cough. While serious AEs were noted in 38% of patients, a little over 10% of patients dropped out of the treatment arm because of AEs. Seventy-seven percent patients had a dose interruption while 66% required a dose reduction.
“Today's approval represents the next step in the development of Zykadia as a treatment option for ALK-positive metastatic NSCLC, bringing this important medication to a patient population where a need still exists,” said Bruno Strigini, CEO, Novartis Oncology, which has developed the drug.
Ceritinib was first approved in 2014 for late-stage NSCLC whose disease advanced on crizotinib or who were intolerant to crizotinib.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More